Alexandria Real Estate Equities Stock Earnings Reports

Alexandria reported a challenging Q1 2026 operating quarter but reiterated disciplined financial plans and strategic priorities. Key operational metrics: leasing volume was 647k sq ft (down), occupancy fell to 87.7% (driven by 657k sq ft of planned expirations), same-property NOI declined ~11.7–11.9% (cash and GAAP) and free-rent/rental-rate pressure impacted quarter results. Positive leasing momentum included 118k sq ft of executed development leases and 276k sq ft of signed LOIs; cumulative leasing of vacant space totaled 1.1M sq ft expected to deliver on average in September. Management reaffirmed FFO per share diluted as adjusted midpoint of $6.40 for 2026 (Q1 FFO $1.73) while tightening ranges and refined the fourth-quarter run-rate range to $1.40–$1.50 (midpoint $1.45). Capital plan and liquidity: $2.9B midpoint target for 2026 dispositions/sales of partial interest (about 80% of that amount is pending/identified), $4.2B liquidity, longest average debt maturity in the S&P 500 REITs (~10 years), and target net debt/EBITDA of 5.6–6.2x by 4Q26. Cost control progress: continued G&A reductions (target $134–$154M for 2026) and reduced capitalized interest guidance (reflecting project pauses/completions). Strategic positioning: mega campuses represent 78% of ARR and top-20 tenants are largely investment-grade or large-cap (≈55% of ARR), supporting long WALT and resilience. Major risks and market context: ongoing FDA and NIH leadership/staffing uncertainty, selective public capital markets (notably zero public biotech leasing in Q1), geopolitical/China pressures on R&D capital flows, and potential near-term occupancy headwinds from expirations in 2026–2027. Management emphasized flexibility—evaluating pivots for five projects (lab vs. advanced-technology uses), potential JVs for core assets, and continued focus on completing the noncore disposition program.